Compare Quest Diagnostics Inc (DGX) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Paychex, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Paychex, Inc. trades at $109.54 (market cap $38.95B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays the higher dividend (4.35%). Which is the better fit depends on your goals.
| DGX | PAYX | |
|---|---|---|
Market Cap | $22.80B | $38.95B |
Sector | Health | Industrials |
52-Week High | $216.02 | $147.99 |
52-Week Low | $166.42 | $85.57 |
Enterprise Value | $28.82B | $42.43B |
Dividend Yield | 1.67% | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Paychex (PAYX) trades at $110.75, up 2.98% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations, and maintains robust profitability with 27.03% net income margin. Recent dividend payment of $1.19 and positive business momentum from AI expansion and small business hiring trends support growth outlook.
Outlook remains positive with steady revenue growth and AI-driven efficiency gains, though valuation multiples appear elevated with P/E of 22.65. Risks include competitive pressures and macroeconomic sensitivity to small business employment trends. Analyst consensus is mixed with 16.67% buy ratings but price target alignment with current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
